$4.54
-0.06 (-1.30%)
Open$4.62
Previous Close$4.60
Day High$4.66
Day Low$4.54
52W High$28.90
52W Low$16.28
Volume—
Avg Volume224.7K
Market Cap40.05M
P/E Ratio—
EPS$-0.74
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+602.2% upside
Current
$4.54
$4.54
Target
$31.88
$31.88
$19.01
$31.88 avg
$45.37
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.32M | 5.21M | 4.72M |
| Net Income | -175,194 | -195,079 | -179,711 |
| Profit Margin | -3.3% | -3.8% | -3.8% |
| EBITDA | -241,242 | -244,954 | -200,080 |
| Free Cash Flow | -156,086 | -167,798 | -115,643 |
| Rev Growth | +3.4% | -0.3% | +24.4% |
| Debt/Equity | 1.52 | 1.55 | 1.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |